The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 2, 2009, Pages 513-519

  Sirohi, Sunil ^a   Dighe, Shveta V ^a   Madia, Priyanka A ^a   Yoburn, Byron C ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE; NALOXONE; NALTREXOL; NALTREXONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG OVERDOSE; DRUG POTENCY; JUMPING; LETHALITY; MALE; MOUSE; NEUROMODULATION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; FENTANYL; MALE; MICE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; RECEPTORS, OPIOID; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 67651048971     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.152678     Document Type: Article

References (28)

1. Becker JA, Wallace A, Garzon A, Ingallinella P, Bianchi E, Cortese R, Simonin F, Kieffer BL, and Pessi A (1999) Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem 274:27513-27522. (Pubitemid 129527795)
2. Burford NT, Wang D, and Sadëe W (2000) G-protein coupling of mu-opioid receptors (OP3): elevated basal signaling activity. Biochem J 348:531-537. (Pubitemid 30410241)
3. Clarke SF, Dargan PI, and Jones AL (2005) Naloxone in opioid poisoning: walking the tightrope. Emerg Med J 22:612-616.
4. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 86:7321-7325. (Pubitemid 19254452)
5. Divin MF, Holden Ko MC, and Traynor JR (2008) Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice. Eur J Pharmacol 583:48-55.
6. Finney DJ (1973) Probit Analysis, 3rd ed., Cambridge University Press, London, UK.
7. Gutstein HB and Akil H (2001) Opioid Analgesics, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., The McGraw-Hill Book Companies, Columbus, OH.
8. Huang P, Li J, Chen C, Visiers I, Weinstein H, and Liu-Chen LY (2001) Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr 6.34(279) with Lys and Asp. Biochemistry 40:13501-13509. (Pubitemid 33130778)
9. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
10. Ko MC, Divin MF, Lee H, Woods JH, and Traynor JR (2006) Differential in vivo potencies of naltrexone and 6β-naltrexol in the monkey. J Pharmacol Exp Ther 316:772-779. (Pubitemid 43131005)
11. Li JX, McMahon LR, and France CP (2008) Comparison of naltrexone, 6alphanaltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys. Psychopharmacology (Berl) 195:479-486.
12. Ling W and Wesson DR (1990) Drugs of abuse-opiates. West J Med 152:565-572.
13. Liu JG and Prather PL (2001) Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 60:53-62.
14. Marczak ED, Jinsmaa Y, Li T, Bryant SD, Tsuda Y, Okada Y, and Lazarus LH (2007) [N-allyl-Dmt1]-endomorphins are micro-opioid receptor antagonists lacking inverse agonist properties. J Pharmacol Exp Ther 323:374-380.
15. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474. (Pubitemid 28051764)
16. Milligan G, MacEwan DJ, Mercouris M, and Mullaney I (1997) Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors. Receptors Channels 5:209-213. (Pubitemid 28242959)
17. Prather PL (2004) Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors. Sci STKE 2004:pe1.
18. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadëe W, and Bilsky EJ (2005) In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioiddependent mice. J Pharmacol Exp Ther 313:1150-1162. (Pubitemid 40727018)
19. Sadëe W, Wang D, and Bilsky EJ (2005) Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-1437. (Pubitemid 40164772)
20. Sirohi S, Dighe SV, Walker EA, and Yoburn BC (2008) The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav 91:115-120.
21. Sirohi S, Kumar P, and Yoburn BC (2007) mu-Opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J Pharmacol Exp Ther 323:701-707. (Pubitemid 350005140)
22. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
23. van Dorp EL, Yassen A, and Dahan A (2007) Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 6:125-132. (Pubitemid 46380806)
24. Walker EA and Sterious SN (2005) Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. Br J Pharmacol 145:975-983.
25. Wang D, Raehal KM, Bilsky EJ, and Sadëe W (2001) Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600. (Pubitemid 32574494)
26. Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, and Sadëe W (2004) Basal signaling activity of μ opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308:512-520. (Pubitemid 38134212)
27. Wang Z, Bilsky EJ, Porreca F, and Sadëe W (1994) Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:PL339-PL350. (Pubitemid 24126825)
28. Wang D, Sun X, and Sadee W (2007) Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321:544-552. (Pubitemid 46624496)